Newport Horizon Premium™ is the most advanced product targeting, global business development and API sourcing system from the Scientific business of Thomson Reuters, the industry authority on the global generics market.

Created specifically for demanding professionals in generic pharmaceutical, OTC and API manufacturing companies, Newport Horizon Premium can help you identify and evaluate new product development and licensing opportunities ahead of the competition — getting you faster to the deal and faster to the market.

Newport Horizon Premium offers the same unique data and features as the respected, industry-standard Horizon Global system with the addition of current and previous year kilogram and International Units (IU) API consumption data by region and by dose form.

API consumption data and trending can be included in sophisticated multi-criteria product targeting searches, further enhancing business value and capability by finding the most appropriate business opportunities to exacting strategic criteria.

• Unique strategic intelligence. Newport Horizon Premium incorporates the unique strategic intelligence and powerful competitive analysis that is only available from Thomson Reuters. It integrates intelligence on more than 10,000 launched products and over 20,000 companies.

• Sophisticated targeting capabilities. Newport Horizon Premium can help you to profile promising new partner companies, identify global product licensing and acquisition opportunities, and secure early, exclusive sources of API supply.

• Test and explore new business strategies. Newport Horizon Premium can help you to recognize potential barriers to market entry, and plan your development pipeline effectively. With the industry’s most sophisticated product targeting capabilities, it can significantly enhance your competitive edge.